Back

Proprotein convertase subtilisin/kexin type 9 levels and the risk of cardiovascular events in statin-treated patients with cardiovascular disease

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering drugs: new insights Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Assistant Professor Masaomi Gohbara

Yokohama City University Medical Center, Yokohama (Japan)

7 More presentations in this session

Presentation thumbnail
The cardiovascular polypill strategy (acetyl salicylic acid, atorvastatin, ramipril) as baseline treatment after a cardiovascular event supported by compelling evidence: a global expert consensus
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention of cardiovascular events
Doctor L. Godoy (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Safety and Efficacy of Moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis
Doctor F. Alves Kelly (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Efficacy and severity of side-effects of rosuvastatin compared to other statins post-heart-transplantation
Ms B. Van Dijk (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Failure of primary prophylaxis: statin use, risk profile, and outcomes in contemporary patients treated with PCI for first atherosclerotic event
Miss H. Anjum (DK)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering drugs: new insights

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
thumbnail
Congress Presentation
The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources